Christopher Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christopher Cai has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Aaron S. Kesselheim
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts
4 shared publicationsBenjamin N. Rome
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts
4 shared publicationsDavid U. Himmelstein
Department of Nutrition and Public Health, Hunter College, City University of New York, New York, New York
4 shared publicationsSteffie Woolhandler
Department of Nutrition and Public Health, Hunter College, City University of New York, New York, New York
4 shared publicationsAdam Gaffney
Cambridge Health Alliance/Harvard Medical School, Cambridge, Massachusetts
2 shared publicationsDanny McCormick
Cambridge Health Alliance/Harvard Medical School, Cambridge, USA
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 7 (6) , e261545
Changes in Medication Use After Medicare Part D Annual Out-of-Pocket Spending Caps
Importance: The Inflation Reduction Act (IRA) implemented annual out-of-pocket spending caps to the Medicare Part D prescription medication benefit in 2024; the caps were lowered to $2000 in 2025. It remains unclear how this policy affected medication access. Objective: To evaluate changes in prescription medication fills in the Medicare population after the implementation of the IRA. Design, Setting, and Participants: This study used data from an all-payer pharmacy database (Symphony Health Metys) to evaluate changes in quarterly prescription fills for medications reimbursed by Medicare and commercial insurance from 2022 to 2025. Using an event study, difference-in-differences framework, changes in per-capita prescriptions for medications before and after the Medicare annual out-of-pocket spending caps were implemented in 2024 were compared. Because out-of-pocket caps are most relevant for patients using expensive medications, medications were stratified based on monthly cost: low (<$100), medium ($100-$829), high ($830-$6999), and very high (≥$7000). Main Outcomes and Measures: Quarterly per-capita fills by medication. Results: Among 3053 medications covering 92.9% of gross Medicare Part D spending in 2023, 1534 (50.2%) were low cost, 882 (28.9%) were medium cost, 455 (14.9%) were high cost, and 182 (6.0%) were very high cost. After the spending caps were implemented, average medication use increased in Medicare compared with medication use in commercial insurance, with larger increases for higher-cost medications. In pre-post difference-in-differences analyses, there was no change in Medicare vs commercial use of low-cost, medium-cost, or high-cost medications. Very-high-cost medication use increased by 22.7% (95% CI, 6.0% to 42.0%; P = .01). Use of medications in Medicare increased over time in event-study analyses, although CIs were wide; by the fourth quarter of 2025, the use of medications in Medicare compared with commercial insurance increased from baseline by 4.1% (95% CI, −3.4% to 12.3%) for low-cost medications, 20.7% (95% CI, −10.7% to 63.0%) for medium-cost medications, 23.1% (95% CI, 2.7% to 47.4%) for high-cost medications, and 35.9% (95% CI, −4.1% to 92.3%) for very-high-cost medications. Conclusions and Relevance: This study found that medication use increased after implementation of Medicare annual out-of-pocket cost caps, particularly among the highest-cost medications. These results suggest that the policy substantially improved patient access to high-cost medications for Medicare-insured patients.
- 1 June 2026
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 7 (6) , e261545
Open AccessChanges in Medication Use After Medicare Part D Annual Out-of-Pocket Spending Caps
Importance: The Inflation Reduction Act (IRA) implemented annual out-of-pocket spending caps to the Medicare Part D prescription medication benefit in 2024; the caps were lowered to $2000 in 2025. It remains unclear how this policy affected medication access. Objective: To evaluate changes in prescription medication fills in the Medicare population after the implementation of the IRA. Design, Setting, and Participants: This study used data from an all-payer pharmacy database (Symphony Health Metys) to evaluate changes in quarterly prescription fills for medications reimbursed by Medicare and commercial insurance from 2022 to 2025. Using an event study, difference-in-differences framework, changes in per-capita prescriptions for medications before and after the Medicare annual out-of-pocket spending caps were implemented in 2024 were compared. Because out-of-pocket caps are most relevant for patients using expensive medications, medications were stratified based on monthly cost: low (<$100), medium ($100-$829), high ($830-$6999), and very high (≥$7000). Main Outcomes and Measures: Quarterly per-capita fills by medication. Results: Among 3053 medications covering 92.9% of gross Medicare Part D spending in 2023, 1534 (50.2%) were low cost, 882 (28.9%) were medium cost, 455 (14.9%) were high cost, and 182 (6.0%) were very high cost. After the spending caps were implemented, average medication use increased in Medicare compared with medication use in commercial insurance, with larger increases for higher-cost medications. In pre-post difference-in-differences analyses, there was no change in Medicare vs commercial use of low-cost, medium-cost, or high-cost medications. Very-high-cost medication use increased by 22.7% (95% CI, 6.0% to 42.0%; P = .01). Use of medications in Medicare increased over time in event-study analyses, although CIs were wide; by the fourth quarter of 2025, the use of medications in Medicare compared with commercial insurance increased from baseline by 4.1% (95% CI, −3.4% to 12.3%) for low-cost medications, 20.7% (95% CI, −10.7% to 63.0%) for medium-cost medications, 23.1% (95% CI, 2.7% to 47.4%) for high-cost medications, and 35.9% (95% CI, −4.1% to 92.3%) for very-high-cost medications. Conclusions and Relevance: This study found that medication use increased after implementation of Medicare annual out-of-pocket cost caps, particularly among the highest-cost medications. These results suggest that the policy substantially improved patient access to high-cost medications for Medicare-insured patients.
- 22 July 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (4) , 360-362
Insurer Exits After the Inflation Reduction Act Part D Redesign
This cross-sectional study examines the number of beneficiaries affected by insurance plans exiting the market following the Inflation Reduction Act redesign of Medicare Part D.
- 22 July 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (4) , 360-362
Insurer Exits After the Inflation Reduction Act Part D Redesign
This cross-sectional study examines the number of beneficiaries affected by insurance plans exiting the market following the Inflation Reduction Act redesign of Medicare Part D.
- 18 March 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (11) , 999-1000
Trends in Fills, Spending, and Prices of Doxepin for Insomnia
This cross-sectional study explores US prescription fills, retail spending, and prices of low-dose doxepin for insomnia and the possible cost savings to patients had they used liquid doxepin, a less expensive formulation.
- 18 March 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (11) , 999-1000
Trends in Fills, Spending, and Prices of Doxepin for Insomnia
This cross-sectional study explores US prescription fills, retail spending, and prices of low-dose doxepin for insomnia and the possible cost savings to patients had they used liquid doxepin, a less expensive formulation.
- Open Access
- 2 January 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (1) , e2454699
Use and Costs of Supplemental Benefits in Medicare Advantage, 2017-2021
Importance: Nearly all Medicare Advantage (MA) plans offer dental, vision, and hearing benefits not covered by traditional Medicare (TM). However, little is known about MA enrollees’ use of those benefits or how much they cost MA insurers or enrollees.Objective: To estimate use, out-of-pocket (OOP) spending, and insurer payments for dental, hearing, and vision services among Medicare beneficiaries.Design, Setting, and Participants: This cross-sectional analysis used pooled 2017-2021 Medical Expenditure Panel Survey (MEPS) and Medicare Current Beneficiary Survey (MCBS) data for MA and TM beneficiaries (excluding those also covered by Medicaid). The analysis was performed from September 10, 2023, to June 30, 2024.Exposures: MA compared with TM coverage.Main Outcomes and Measures: The main outcome was receipt of eye examinations, corrective lenses, hearing aids, optometry and dental visits, and MA and TM enrollees’ and insurers’ spending for such services. MEPS and MCBS data were weighted to be nationally representative.Results: We included 76 557 non–dually eligible Medicare beneficiaries, including 23 404 from the MEPS and 53 153 from the MCBS. Weighted demographic characteristics of MA and TM beneficiaries were similar (54.7% and 51.9% female; 39.8% and 35.2% older than 75 years, respectively). Only 54.2% (95% CI, 52.4%-55.9%) and 54.3% (95% CI 52.2%-56.3%) of MA beneficiaries were aware of having MA dental and vision coverage, respectively. MA enrollees were no more likely to receive eye examinations, hearing aids, or eyeglasses than TM enrollees. After adjustment for demographic differences, MA and TM enrollees paid OOP $205.86 (95% CI, $192.44-$219.27) and $226.12 (95% CI, $212.02-$240.23), respectively, for eyeglasses (MA − TM difference, −$20.27 [95% CI, −$33.77 to −$6.77] or −9.0% [95% CI, −14.9% to −3.0%]); $226.82 (95% CI, $202.24-$251.40) and $249.98 (95% CI, $226.22-$273.74) for dental visits, respectively (MA − TM difference, −$23.16 [95% CI, −$43.15 to −$3.17] or −9.3% [95% CI, −17.3% to −1.3%]); and no less for optometry visits or durable medical equipment (a proxy for hearing aids). Nationwide, MA plans’ annual spending on vision, dental services, and durable medical equipment totaled $3.9 billion (95% CI, $3.3-$4.4 billion), while enrollees spent OOP $9.2 billion (95% CI, $8.2-$10.2 billion) annually for these services and other private insurers covered $2.8 billion (95% CI, $2.7-$3.0 billion).Conclusions and Relevance: In this cross-sectional study of 2 nationally representative surveys, MA beneficiaries did not receive more supplemental services than TM beneficiaries, possibly because of cost-sharing and limited awareness of benefit coverage.
- 2 January 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (1) , e2454699
Open AccessUse and Costs of Supplemental Benefits in Medicare Advantage, 2017-2021
Importance: Nearly all Medicare Advantage (MA) plans offer dental, vision, and hearing benefits not covered by traditional Medicare (TM). However, little is known about MA enrollees’ use of those benefits or how much they cost MA insurers or enrollees.Objective: To estimate use, out-of-pocket (OOP) spending, and insurer payments for dental, hearing, and vision services among Medicare beneficiaries.Design, Setting, and Participants: This cross-sectional analysis used pooled 2017-2021 Medical Expenditure Panel Survey (MEPS) and Medicare Current Beneficiary Survey (MCBS) data for MA and TM beneficiaries (excluding those also covered by Medicaid). The analysis was performed from September 10, 2023, to June 30, 2024.Exposures: MA compared with TM coverage.Main Outcomes and Measures: The main outcome was receipt of eye examinations, corrective lenses, hearing aids, optometry and dental visits, and MA and TM enrollees’ and insurers’ spending for such services. MEPS and MCBS data were weighted to be nationally representative.Results: We included 76 557 non–dually eligible Medicare beneficiaries, including 23 404 from the MEPS and 53 153 from the MCBS. Weighted demographic characteristics of MA and TM beneficiaries were similar (54.7% and 51.9% female; 39.8% and 35.2% older than 75 years, respectively). Only 54.2% (95% CI, 52.4%-55.9%) and 54.3% (95% CI 52.2%-56.3%) of MA beneficiaries were aware of having MA dental and vision coverage, respectively. MA enrollees were no more likely to receive eye examinations, hearing aids, or eyeglasses than TM enrollees. After adjustment for demographic differences, MA and TM enrollees paid OOP $205.86 (95% CI, $192.44-$219.27) and $226.12 (95% CI, $212.02-$240.23), respectively, for eyeglasses (MA − TM difference, −$20.27 [95% CI, −$33.77 to −$6.77] or −9.0% [95% CI, −14.9% to −3.0%]); $226.82 (95% CI, $202.24-$251.40) and $249.98 (95% CI, $226.22-$273.74) for dental visits, respectively (MA − TM difference, −$23.16 [95% CI, −$43.15 to −$3.17] or −9.3% [95% CI, −17.3% to −1.3%]); and no less for optometry visits or durable medical equipment (a proxy for hearing aids). Nationwide, MA plans’ annual spending on vision, dental services, and durable medical equipment totaled $3.9 billion (95% CI, $3.3-$4.4 billion), while enrollees spent OOP $9.2 billion (95% CI, $8.2-$10.2 billion) annually for these services and other private insurers covered $2.8 billion (95% CI, $2.7-$3.0 billion).Conclusions and Relevance: In this cross-sectional study of 2 nationally representative surveys, MA beneficiaries did not receive more supplemental services than TM beneficiaries, possibly because of cost-sharing and limited awareness of benefit coverage.
- 1 November 2024
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 184 (11) , 1390-1392
Estimated Savings Under the Medicare High-Value Drug List Model
This cross-sectional study describes potential reductions in out-of-pocket costs for generic medications among Medicare beneficiaries.
- 1 November 2024
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 184 (11) , 1390-1392
Estimated Savings Under the Medicare High-Value Drug List Model
This cross-sectional study describes potential reductions in out-of-pocket costs for generic medications among Medicare beneficiaries.
- 1 May 2024
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 43 (5) , 666-673
Protecting Patients And Society In An Era Of Private Equity Provider Ownership: Challenges And Opportunities For Policy
Private equity (PE) acquisitions in health care delivery nearly tripled from 2010 to 2020. Despite concerns around clinical and economic implications, policy responses have remained limited. We discuss the US policy landscape around PE ownership, using policies in the European Union for comparison. We present four domains in which policy can be strengthened. First, to improve oversight of acquisitions, policy makers should lower reporting thresholds, review sequential acquisitions that together affect market power, automate reviews with potential denials based on market concentration effects, consider new regulatory mechanisms such as attorney general veto, and increase funding for this work. Second, policy makers should increase the longer-run transparency of PE ownership, including the health care prices garnered by acquired entities. Third, policy makers should protect patients and providers by establishing minimum staffing ratios, spending floors for direct patient care, and limits on layoffs and the sale of real estate after acquisition (forms of "asset stripping"). Finally, policy makers should mitigate risky financial behavior by limiting the amount or proportion of debt used to finance PE acquisitions in health care.
- 1 May 2024
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 43 (5) , 666-673
Protecting Patients And Society In An Era Of Private Equity Provider Ownership: Challenges And Opportunities For Policy
Private equity (PE) acquisitions in health care delivery nearly tripled from 2010 to 2020. Despite concerns around clinical and economic implications, policy responses have remained limited. We discuss the US policy landscape around PE ownership, using policies in the European Union for comparison. We present four domains in which policy can be strengthened. First, to improve oversight of acquisitions, policy makers should lower reporting thresholds, review sequential acquisitions that together affect market power, automate reviews with potential denials based on market concentration effects, consider new regulatory mechanisms such as attorney general veto, and increase funding for this work. Second, policy makers should increase the longer-run transparency of PE ownership, including the health care prices garnered by acquired entities. Third, policy makers should protect patients and providers by establishing minimum staffing ratios, spending floors for direct patient care, and limits on layoffs and the sale of real estate after acquisition (forms of "asset stripping"). Finally, policy makers should mitigate risky financial behavior by limiting the amount or proportion of debt used to finance PE acquisitions in health care.
- 9 May 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 329 (18) , 1545-1546
A Policy Framework for the Growing Influence of Private Equity in Health Care Delivery
This Viewpoint details how and why improved oversight of private equity acquisition of physician practices and hospitals is needed to mitigate the effects on health care costs, clinicians’ jobs, and patients’ access to care.
- 9 May 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 329 (18) , 1545-1546
A Policy Framework for the Growing Influence of Private Equity in Health Care Delivery
This Viewpoint details how and why improved oversight of private equity acquisition of physician practices and hospitals is needed to mitigate the effects on health care costs, clinicians’ jobs, and patients’ access to care.
- 6 June 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (2) , 434-441
Trends and Disparities in the Distribution of Outpatient Physicians’ Annual Face Time with Patients, 1979–2018
Background Physician time is a valuable yet finite resource. Whether such time is apportioned equitably among population subgroups, and how the provision of that time has changed in recent decades, is unclear. Objective To investigate trends and racial/ethnic disparities in the receipt of annual face time with physicians in the USA. Design Repeated cross-sectional. Setting National Ambulatory Medical Care Survey, 1979–1981, 1985, 1989–2016, 2018. Participants Office-based physicians. Measures Exposures included race/ethnicity (White, Black, and Hispanic); age (n=1,108,835 patient visits. From 1979 to 2018, annual outpatient physician face time per capita rose from 40.0 to 60.4 min, an increase driven by a rise in mean visit length and not in the number of visits. However, since 2005, mean annual face time with a primary care physician has fallen, a decline offset by rising time with specialists. Face time provided per physician changed little given growth in the physician workforce. A racial/ethnic gap in physician visit time present at the beginning of the study period widened over time. In 2014–2018, White individuals received 70.0 min of physician face time per year, vs. 52.4 among Black and 53.0 among Hispanic individuals. This disparity was driven by differences in visit rates, not mean visit length, and in the provision of specialist but not primary care. Limitation Self-reported visit length. Conclusion Americans’ annual face time with office-based physicians rose for three decades after 1979, yet is still allocated inequitably, particularly by specialists; meanwhile, time spent by Americans with primary care physicians is falling. These trends and disparities may adversely affect patient outcomes. Policy change is needed to assure better allocation of this resource.
- 6 June 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (2) , 434-441
Trends and Disparities in the Distribution of Outpatient Physicians’ Annual Face Time with Patients, 1979–2018
Background Physician time is a valuable yet finite resource. Whether such time is apportioned equitably among population subgroups, and how the provision of that time has changed in recent decades, is unclear. Objective To investigate trends and racial/ethnic disparities in the receipt of annual face time with physicians in the USA. Design Repeated cross-sectional. Setting National Ambulatory Medical Care Survey, 1979–1981, 1985, 1989–2016, 2018. Participants Office-based physicians. Measures Exposures included race/ethnicity (White, Black, and Hispanic); age (n=1,108,835 patient visits. From 1979 to 2018, annual outpatient physician face time per capita rose from 40.0 to 60.4 min, an increase driven by a rise in mean visit length and not in the number of visits. However, since 2005, mean annual face time with a primary care physician has fallen, a decline offset by rising time with specialists. Face time provided per physician changed little given growth in the physician workforce. A racial/ethnic gap in physician visit time present at the beginning of the study period widened over time. In 2014–2018, White individuals received 70.0 min of physician face time per year, vs. 52.4 among Black and 53.0 among Hispanic individuals. This disparity was driven by differences in visit rates, not mean visit length, and in the provision of specialist but not primary care. Limitation Self-reported visit length. Conclusion Americans’ annual face time with office-based physicians rose for three decades after 1979, yet is still allocated inequitably, particularly by specialists; meanwhile, time spent by Americans with primary care physicians is falling. These trends and disparities may adversely affect patient outcomes. Policy change is needed to assure better allocation of this resource.
- 9 February 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 37 (13) , 3501-3503
Racial and Ethnic Inequities in Diabetes Pharmacotherapy: Black and Hispanic Patients Are Less Likely to Receive SGLT2is and GLP1as
- 9 February 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 37 (13) , 3501-3503
Racial and Ethnic Inequities in Diabetes Pharmacotherapy: Black and Hispanic Patients Are Less Likely to Receive SGLT2is and GLP1as
- 8 February 2022
- Published by Taylor & Francis in Journal of Social Distress and Homelessness
- Vol. 32 (2) , 200-209
Barriers and facilitators to resolving older adult homelessness through stays with family: qualitative findings from the HOPE HOME study
Living with family and friends is a common strategy to prevent or exit homelessness, but little is known about structural barriers that impede family and friends’ ability to provide temporary or permanent housing for older homeless adults. We conducted semi-structured interviews with 46 homeless participants from the HOPE HOME study, a cohort of 350 community-recruited homeless adults age 50 or older in Oakland, CA, who reported staying with housed family/friends for 1 or more nights in the prior 6 months. We conducted semi-structured interviews with 19 hosts of homeless participants and 11 stakeholders in housing and homelessness. We found that homeless older adults and hosts perceived these stays as a form of temporary housing rather than as a permanent exit to homelessness. Structural barriers to family and friends providing housing for temporary stays or permanent exits from homelessness included housing regulations restricting visitors and changing rent obligations; decreased eligibility and priority for shelter and permanent housing; geographic and transportation challenges; and environments inconducive to older adults. We suggest four areas for policy reform: providing subsidies to hosts and homeless individuals, removing disincentives for homeless older adults to stay with family, changing lease regulations, and expanding the supply of affordable housing.
- 8 February 2022
- Published by Taylor & Francis in Journal of Social Distress and Homelessness
- Vol. 32 (2) , 200-209
Barriers and facilitators to resolving older adult homelessness through stays with family: qualitative findings from the HOPE HOME study
Living with family and friends is a common strategy to prevent or exit homelessness, but little is known about structural barriers that impede family and friends’ ability to provide temporary or permanent housing for older homeless adults. We conducted semi-structured interviews with 46 homeless participants from the HOPE HOME study, a cohort of 350 community-recruited homeless adults age 50 or older in Oakland, CA, who reported staying with housed family/friends for 1 or more nights in the prior 6 months. We conducted semi-structured interviews with 19 hosts of homeless participants and 11 stakeholders in housing and homelessness. We found that homeless older adults and hosts perceived these stays as a form of temporary housing rather than as a permanent exit to homelessness. Structural barriers to family and friends providing housing for temporary stays or permanent exits from homelessness included housing regulations restricting visitors and changing rent obligations; decreased eligibility and priority for shelter and permanent housing; geographic and transportation challenges; and environments inconducive to older adults. We suggest four areas for policy reform: providing subsidies to hosts and homeless individuals, removing disincentives for homeless older adults to stay with family, changing lease regulations, and expanding the supply of affordable housing.